Ignite Creation Date:
2024-05-06 @ 5:58 PM
Last Modification Date:
2024-10-26 @ 2:39 PM
Study NCT ID:
NCT05495724
Status:
RECRUITING
Last Update Posted:
2022-08-10
First Post:
2022-08-09
Brief Title:
Disitamab Vedotin Combined With Tislelizumab for Her2 Overexpressing High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable
Sponsor:
Organization:
Tianjin Medical University Second Hospital